448 related articles for article (PubMed ID: 24618912)
1. Current concepts in breast cancer chemoprevention.
Chlebowski RT
Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
[TBL] [Abstract][Full Text] [Related]
2. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
4. Preventive therapy for breast cancer: a consensus statement.
Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
[TBL] [Abstract][Full Text] [Related]
5. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
6. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
7. Personalized prevention in high risk individuals: Managing hormones and beyond.
Evans DG; Howell SJ; Howell A
Breast; 2018 Jun; 39():139-147. PubMed ID: 29610032
[TBL] [Abstract][Full Text] [Related]
8. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Barros-Oliveira MDC; Costa-Silva DR; Andrade DB; Borges US; Tavares CB; Borges RS; Silva JM; Silva BBD
Rev Assoc Med Bras (1992); 2017 Apr; 63(4):371-378. PubMed ID: 28614542
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Mocellin S; Pilati P; Briarava M; Nitti D
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
[TBL] [Abstract][Full Text] [Related]
10. Use of aromatase inhibitors in breast carcinoma.
Santen RJ; Harvey HA
Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of endocrine therapy in breast cancer.
Ingle JN
J Hum Genet; 2013 Jun; 58(6):306-12. PubMed ID: 23635953
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
14. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
15. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
16. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer chemoprevention.
Gabriel EM; Jatoi I
Expert Rev Anticancer Ther; 2012 Feb; 12(2):223-8. PubMed ID: 22316370
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]